More than a decade ago, the US Food and Drug Administration approved an autologous cellular therapy, Provenge (sipuleucel-T), to treat prostate cancer. At the time, it was the first therapeutic cancer vaccine to be approved in the US. Developed by Dendreon Corp, the vaccine later changed hands twice, entering the portfolio of a private Chinese conglomerate, Sanpower Group in 2017.
